BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hong GK, Kumar P, Wang L, Damania B, Gulley ML, Delecluse HJ, Polverini PJ, Kenney SC. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 2005;79:13984-92. [PMID: 16254334 DOI: 10.1128/JVI.79.22.13984-13992.2005] [Cited by in Crossref: 76] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Habib M, Buisson M, Lupo J, Agbalika F, Socié G, Germi R, Baccard M, Imbert-Marcille BM, Dantal J, Morand P, Drouet E. Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD. Sci Rep 2017;7:10479. [PMID: 28874674 DOI: 10.1038/s41598-017-09798-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
2 Sato Y, Kamura T, Shirata N, Murata T, Kudoh A, Iwahori S, Nakayama S, Isomura H, Nishiyama Y, Tsurumi T. Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex. PLoS Pathog 2009;5:e1000530. [PMID: 19649319 DOI: 10.1371/journal.ppat.1000530] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 6.0] [Reference Citation Analysis]
3 Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC. X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J Virol 2007;81:7363-70. [PMID: 17494074 DOI: 10.1128/JVI.00154-07] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 5.9] [Reference Citation Analysis]
4 Yiu CY, Chen SY, Yang TH, Chang CJ, Yeh DB, Chen YJ, Lin TP. Inhibition of Epstein-Barr virus lytic cycle by an ethyl acetate subfraction separated from Polygonum cuspidatum root and its major component, emodin. Molecules 2014;19:1258-72. [PMID: 24448066 DOI: 10.3390/molecules19011258] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
5 Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol. 2011;85:165-177. [PMID: 20980506 DOI: 10.1128/jvi.01512-10] [Cited by in Crossref: 192] [Cited by in F6Publishing: 134] [Article Influence: 16.0] [Reference Citation Analysis]
6 Trompet E, Temblador A, Gillemot S, Topalis D, Snoeck R, Andrei G. An MHV-68 Mutator Phenotype Mutant Virus, Confirmed by CRISPR/Cas9-Mediated Gene Editing of the Viral DNA Polymerase Gene, Shows Reduced Viral Fitness. Viruses 2021;13:985. [PMID: 34073189 DOI: 10.3390/v13060985] [Reference Citation Analysis]
7 Wen W, Iwakiri D, Yamamoto K, Maruo S, Kanda T, Takada K. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J Virol. 2007;81:1037-1042. [PMID: 17079287 DOI: 10.1128/jvi.01416-06] [Cited by in Crossref: 80] [Cited by in F6Publishing: 58] [Article Influence: 5.0] [Reference Citation Analysis]
8 Wu CC, Fang CY, Hsu HY, Chuang HY, Cheng YJ, Chen YJ, Chou SP, Huang SY, Lin SF, Chang Y, Tsai CH, Chen JY. EBV reactivation as a target of luteolin to repress NPC tumorigenesis. Oncotarget 2016;7:18999-9017. [PMID: 26967558 DOI: 10.18632/oncotarget.7967] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
9 Wang P, Day L, Lieberman PM. Multivalent sequence recognition by Epstein-Barr virus Zta requires cysteine 171 and an extension of the canonical B-ZIP domain. J Virol 2006;80:10942-9. [PMID: 16971443 DOI: 10.1128/JVI.00907-06] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
10 Lee S, Salwinski L, Zhang C, Chu D, Sampankanpanich C, Reyes NA, Vangeloff A, Xing F, Li X, Wu TT, Sahasrabudhe S, Deng H, Lacount DJ, Sun R. An integrated approach to elucidate the intra-viral and viral-cellular protein interaction networks of a gamma-herpesvirus. PLoS Pathog 2011;7:e1002297. [PMID: 22028648 DOI: 10.1371/journal.ppat.1002297] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
11 Mansouri S, Pan Q, Blencowe BJ, Claycomb JM, Frappier L. Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. J Virol 2014;88:11166-77. [PMID: 25031339 DOI: 10.1128/JVI.01785-14] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
12 Liapis K, Clear A, Owen A, Coutinho R, Greaves P, Lee AM, Montoto S, Calaminici M, Gribben JG. The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood. 2013;122:424-433. [PMID: 23652804 DOI: 10.1182/blood-2013-03-488171] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
13 Sivachandran N, Wang X, Frappier L. Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection. J Virol 2012;86:6146-58. [PMID: 22491455 DOI: 10.1128/JVI.00013-12] [Cited by in Crossref: 65] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
14 Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol. 2014;26:60-68. [PMID: 24457012 DOI: 10.1016/j.semcancer.2014.01.002] [Cited by in Crossref: 151] [Cited by in F6Publishing: 145] [Article Influence: 18.9] [Reference Citation Analysis]
15 Feederle R, Bartlett EJ, Delecluse HJ. Epstein-Barr virus genetics: talking about the BAC generation. Herpesviridae 2010;1:6. [PMID: 21429237 DOI: 10.1186/2042-4280-1-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
16 Linnerbauer S, Behrends U, Adhikary D, Witter K, Bornkamm GW, Mautner J. Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders. PLoS Pathog 2014;10:e1004068. [PMID: 24853673 DOI: 10.1371/journal.ppat.1004068] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
17 Yoon C, Kim J, Park G, Kim S, Kim D, Hur DY, Kim B, Kim YS. Delivery of miR-155 to retinal pigment epithelial cells mediated by Burkitt's lymphoma exosomes. Tumour Biol 2016;37:313-21. [PMID: 26211004 DOI: 10.1007/s13277-015-3769-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
18 Ramasubramanyan S, Kanhere A, Osborn K, Flower K, Jenner RG, Sinclair AJ. Genome-wide analyses of Zta binding to the Epstein-Barr virus genome reveals interactions in both early and late lytic cycles and an epigenetic switch leading to an altered binding profile. J Virol 2012;86:12494-502. [PMID: 23015699 DOI: 10.1128/JVI.01705-12] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
19 Hu J, Li Y, Li H, Shi F, Xie L, Zhao L, Tang M, Luo X, Jia W, Fan J, Zhou J, Gao Q, Qiu S, Wu W, Zhang X, Liao W, Bode AM, Cao Y. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy. Theranostics 2020;10:11921-37. [PMID: 33204320 DOI: 10.7150/thno.46006] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
20 Albatati S, Sharma A, Haubrich K, Wright A, Gantt S, Blydt-Hansen TD. Valganciclovir prophylaxis delays onset of EBV viremia in high-risk pediatric solid organ transplant recipients. Pediatr Res 2020;87:892-6. [PMID: 31377753 DOI: 10.1038/s41390-019-0523-4] [Reference Citation Analysis]
21 Petrara MR, Freguja R, Gianesin K, Zanchetta M, De Rossi A. Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front Microbiol. 2013;4:311. [PMID: 24151490 DOI: 10.3389/fmicb.2013.00311] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
22 Li H, Liu S, Hu J, Luo X, Li N, M Bode A, Cao Y. Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis. Int J Biol Sci 2016;12:1309-18. [PMID: 27877083 DOI: 10.7150/ijbs.16564] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 9.8] [Reference Citation Analysis]
23 Hsu M, Wu SY, Chang SS, Su IJ, Tsai CH, Lai SJ, Shiau AL, Takada K, Chang Y. Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. J Virol 2008;82:3679-88. [PMID: 18234802 DOI: 10.1128/JVI.02301-07] [Cited by in Crossref: 54] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
24 Paydas S. Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity. Med Oncol 2012;29:2159-65. [PMID: 21948392 DOI: 10.1007/s12032-011-0065-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
25 Wu CC, Fang CY, Cheng YJ, Hsu HY, Chou SP, Huang SY, Tsai CH, Chen JY. Inhibition of Epstein-Barr virus reactivation by the flavonoid apigenin. J Biomed Sci 2017;24:2. [PMID: 28056971 DOI: 10.1186/s12929-016-0313-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
26 Mora AL, Torres-González E, Rojas M, Xu J, Ritzenthaler J, Speck SH, Roman J, Brigham K, Stecenko A. Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice. Am J Respir Crit Care Med 2007;175:1139-50. [PMID: 17363768 DOI: 10.1164/rccm.200610-1426OC] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
27 Hui KF, Yiu SPT, Tam KP, Chiang AKS. Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases. Front Oncol 2019;9:81. [PMID: 30873380 DOI: 10.3389/fonc.2019.00081] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
28 Granato M, Romeo MA, Tiano MS, Santarelli R, Gonnella R, Gilardini Montani MS, Faggioni A, Cirone M. Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy. Sci Rep 2017;7:13052. [PMID: 29026157 DOI: 10.1038/s41598-017-13533-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
29 Bristol JA, Djavadian R, Albright ER, Coleman CB, Ohashi M, Hayes M, Romero-Masters JC, Barlow EA, Farrell PJ, Rochford R, Kalejta RF, Johannsen EC, Kenney SC. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection. PLoS Pathog 2018;14:e1007179. [PMID: 30052684 DOI: 10.1371/journal.ppat.1007179] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
30 Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, Weber DM, Orlowski RZ. Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. Clin Cancer Res 2016;22:4901-12. [PMID: 27297582 DOI: 10.1158/1078-0432.CCR-15-2242] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
31 Yiu CY, Chen SY, Chang LK, Chiu YF, Lin TP. Inhibitory effects of resveratrol on the Epstein-Barr virus lytic cycle. Molecules 2010;15:7115-24. [PMID: 20948499 DOI: 10.3390/molecules15107115] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
32 Inagaki T, Sato Y, Ito J, Takaki M, Okuno Y, Yaguchi M, Masud HMAA, Watanabe T, Sato K, Iwami S, Murata T, Kimura H. Direct Evidence of Abortive Lytic Infection-Mediated Establishment of Epstein-Barr Virus Latency During B-Cell Infection. Front Microbiol 2020;11:575255. [PMID: 33613459 DOI: 10.3389/fmicb.2020.575255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Ryan JL, Morgan DR, Dominguez RL, Thorne LB, Elmore SH, Mino-Kenudson M, Lauwers GY, Booker JK, Gulley ML. High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma. Lab Invest 2009;89:80-90. [PMID: 19002111 DOI: 10.1038/labinvest.2008.103] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
34 Teow SY, Yap HY, Peh SC. Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment. J Pathog 2017;2017:7349268. [PMID: 29464124 DOI: 10.1155/2017/7349268] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
35 Wang P, Rennekamp AJ, Yuan Y, Lieberman PM. Topoisomerase I and RecQL1 function in Epstein-Barr virus lytic reactivation. J Virol 2009;83:8090-8. [PMID: 19494003 DOI: 10.1128/JVI.02379-08] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
36 Rennekamp AJ, Lieberman PM. Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism. Future Virol 2010;5:65-83. [PMID: 22468146 DOI: 10.2217/fvl.09.69] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
37 Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol. 2005;79:13993-14003. [PMID: 16254335 DOI: 10.1128/jvi.79.22.13993-14003.2005] [Cited by in Crossref: 155] [Cited by in F6Publishing: 98] [Article Influence: 9.7] [Reference Citation Analysis]
38 Lee CH, Yeh TH, Lai HC, Wu SY, Su IJ, Takada K, Chang Y. Epstein-Barr virus Zta-induced immunomodulators from nasopharyngeal carcinoma cells upregulate interleukin-10 production from monocytes. J Virol 2011;85:7333-42. [PMID: 21543473 DOI: 10.1128/JVI.00182-11] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
39 Taylor JG, Liapis K, Gribben JG. The role of the tumor microenvironment in HIV-associated lymphomas. Biomark Med 2015;9:473-82. [PMID: 25985176 DOI: 10.2217/bmm.15.13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
40 Rivera-Soto R, Damania B. Modulation of Angiogenic Processes by the Human Gammaherpesviruses, Epstein-Barr Virus and Kaposi's Sarcoma-Associated Herpesvirus. Front Microbiol 2019;10:1544. [PMID: 31354653 DOI: 10.3389/fmicb.2019.01544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
41 Germini D, Sall FB, Shmakova A, Wiels J, Dokudovskaya S, Drouet E, Vassetzky Y. Oncogenic Properties of the EBV ZEBRA Protein. Cancers (Basel) 2020;12:E1479. [PMID: 32517128 DOI: 10.3390/cancers12061479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
42 Choi CK, Ho DN, Hui KF, Kao RY, Chiang AK. Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies. PLoS One 2015;10:e0145994. [PMID: 26717578 DOI: 10.1371/journal.pone.0145994] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
43 Iempridee T, Reusch JA, Riching A, Johannsen EC, Dovat S, Kenney SC, Mertz JE. Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells. J Virol 2014;88:4811-27. [PMID: 24522918 DOI: 10.1128/JVI.03706-13] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
44 Rennekamp AJ, Wang P, Lieberman PM. Evidence for DNA hairpin recognition by Zta at the Epstein-Barr virus origin of lytic replication. J Virol 2010;84:7073-82. [PMID: 20444899 DOI: 10.1128/JVI.02666-09] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
45 Wiedmer A, Wang P, Zhou J, Rennekamp AJ, Tiranti V, Zeviani M, Lieberman PM. Epstein-Barr virus immediate-early protein Zta co-opts mitochondrial single-stranded DNA binding protein to promote viral and inhibit mitochondrial DNA replication. J Virol 2008;82:4647-55. [PMID: 18305033 DOI: 10.1128/JVI.02198-07] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
46 Romero-Masters JC, Huebner SM, Ohashi M, Bristol JA, Benner BE, Barlow EA, Turk GL, Nelson SE, Baiu DC, Van Sciver N, Ranheim EA, Gumperz J, Sherer NM, Farrell PJ, Johannsen EC, Kenney SC. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection. PLoS Pathog 2020;16:e1008365. [PMID: 32059024 DOI: 10.1371/journal.ppat.1008365] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
47 Li H, Hu J, Luo X, Bode AM, Dong Z, Cao Y. Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies. Cancer Sci 2018;109:2101-8. [PMID: 29751367 DOI: 10.1111/cas.13634] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
48 Png YT, Yang AZY, Lee MY, Chua MJM, Lim CM. The Role of NK Cells in EBV Infection and EBV-Associated NPC. Viruses 2021;13:300. [PMID: 33671917 DOI: 10.3390/v13020300] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Andrei G, Trompet E, Snoeck R. Novel Therapeutics for Epstein⁻Barr Virus. Molecules 2019;24:E997. [PMID: 30871092 DOI: 10.3390/molecules24050997] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
50 Rosemarie Q, Sugden B. Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis. Microorganisms 2020;8:E1824. [PMID: 33228078 DOI: 10.3390/microorganisms8111824] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
51 Cai Q, Chen K, Young KH. Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders. Exp Mol Med 2015;47:e133. [PMID: 25613730 DOI: 10.1038/emm.2014.105] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]